Article
Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study.
European journal of cancer (Oxford, England : 1990) - 1 Aug 2023
Bachet Jean-Baptiste, Laurent-Puig Pierre, Meurisse Aurelia, Bouché Olivier, Mas Léo, Taly Valérie, Cohen Romain, Gornet Jean-Marc, Artru Pascal, Louafi Samy, Thirot-Bidault Anne, Baumgaertner Isabelle, Coriat Romain, Tougeron David, Lecomte Thierry, Mary Florence, Aparicio Thomas, Marthey Lysiane, Blons Hélène, Vernerey Dewy, Taieb Julien
Abstract excerpt
PURPOSE: Baseline circulating tumour DNA (ctDNA) is a potential prognostic marker in metastatic colorectal cancer (mCRC) patients. However, few studies have compared ctDNA with the usual prognostic factors, and no ctDNA cut-off has been proposed for daily use in clinical practice. PATIENTS AND METHODS: Chemotherapy-naive patients with mCRC were prospectively included. Plasma samples were collected at diagnosis...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
